{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:48Z","timestamp":1791613668889,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002655","name":"Terry Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:26:39Z","timestamp":1706801199000},"page":"305-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cereblon-Targeting Ligase Degraders in Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Holly","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5971","key":"10.1016\/j.hoc.2024.01.001_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science (New York, NY)"},{"issue":"9","key":"10.1016\/j.hoc.2024.01.001_bib2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"6168","key":"10.1016\/j.hoc.2024.01.001_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science (New York, NY)"},{"issue":"6168","key":"10.1016\/j.hoc.2024.01.001_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science (New York, NY)"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0092-8674(94)90407-3","article-title":"The Ikaros gene is required for the development of all lymphoid lineages","volume":"79","author":"Georgopoulos","year":"1994","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0952-7915(99)80028-4","article-title":"Control of lymphocyte development by the Ikaros gene family","volume":"11","author":"Cortes","year":"1999","journal-title":"Curr Opin Immunol"},{"issue":"18","key":"10.1016\/j.hoc.2024.01.001_bib7","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2008.07442.x","article-title":"The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia","volume":"144","author":"N\u00fcckel","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.001_bib9","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/emboj\/16.8.2004","article-title":"Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation","volume":"16","author":"Morgan","year":"1997","journal-title":"Embo j"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1084\/jem.20031571","article-title":"Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity","volume":"199","author":"Cort\u00e9s","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A\u00a0Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J\u00a0Med Chem"},{"issue":"13","key":"10.1016\/j.hoc.2024.01.001_bib12","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.hoc.2024.01.001_bib13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"6619","key":"10.1016\/j.hoc.2024.01.001_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science (New York, NY)"},{"issue":"7933","key":"10.1016\/j.hoc.2024.01.001_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41586-022-05333-5","article-title":"The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron","volume":"610","author":"Ichikawa","year":"2022","journal-title":"Nature"},{"issue":"6414","key":"10.1016\/j.hoc.2024.01.001_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.hoc.2024.01.001_bib17","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2024.01.001_bib18","doi-asserted-by":"crossref","first-page":"e38430","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib19","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"issue":"7559","key":"10.1016\/j.hoc.2024.01.001_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"7597","key":"10.1016\/j.hoc.2024.01.001_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4(CRBN) ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"issue":"7611","key":"10.1016\/j.hoc.2024.01.001_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A\u00a0novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2024.01.001_bib23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.001_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.001_bib26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood-2016-09-738872","article-title":"Multiple myeloma cells' capacity to decompose H(2)O(2) determines lenalidomide sensitivity","volume":"129","author":"Sebastian","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2024.01.001_bib27","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T\u00a0cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2024.01.001_bib28","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.001_bib29","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T\u00a0cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"issue":"10","key":"10.1016\/j.hoc.2024.01.001_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1089\/jir.2005.25.604","article-title":"Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T\u00a0cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT","volume":"25","author":"Payvandi","year":"2005","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.001_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.immuni.2007.02.010","article-title":"Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits","volume":"26","author":"Thompson","year":"2007","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.001_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1074-7613(00)80033-3","article-title":"Ikaros sets thresholds for T\u00a0cell activation and regulates chromosome propagation","volume":"10","author":"Avitahl","year":"1999","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.001_bib33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ni.2363","article-title":"Aiolos promotes TH17 differentiation by directly silencing Il2 expression","volume":"13","author":"Quintana","year":"2012","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2024.01.001_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T\u00a0cells by inducing degradation of T\u00a0cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T\u00a0cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2024.01.001_bib39","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer immunology, immunotherapy CII"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/0008-5472.CAN-05-2429","article-title":"Natural killer cells produce T\u00a0cell-recruiting chemokines in response to antibody-coated tumor cells","volume":"66","author":"Roda","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.001_bib41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer immunology, immunotherapy CII"},{"issue":"10","key":"10.1016\/j.hoc.2024.01.001_bib42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br J Cancer"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2024.01.001_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in\u00a0vivo and inhibits endothelial cell migration and Akt phosphorylation in\u00a0vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"issue":"12","key":"10.1016\/j.hoc.2024.01.001_bib44","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2024.01.001_bib45","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2024.01.001_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"issue":"10","key":"10.1016\/j.hoc.2024.01.001_bib47","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2024.01.001_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2024.01.001_bib50","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2024.01.001_bib51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V128.22.120.120","article-title":"Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial","volume":"128","author":"Neri","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2024.01.001_bib52","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2024.01.001_bib53","doi-asserted-by":"crossref","first-page":"831779","DOI":"10.3389\/fgene.2022.831779","article-title":"Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways","volume":"13","author":"Karagoz","year":"2022","journal-title":"Front Genet"},{"issue":"18","key":"10.1016\/j.hoc.2024.01.001_bib54","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.2020010452","article-title":"Cereblon enhancer methylation and IMiD resistance in multiple myeloma","volume":"138","author":"Haertle","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2024.01.001_bib55","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.2019000789","article-title":"Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs","volume":"134","author":"Sperling","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib57","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"10.1016\/j.hoc.2024.01.001_bib60","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.hoc.2024.01.001_bib61","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib62","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","article-title":"A\u00a0genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity","volume":"33","author":"Liu","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2024.01.001_bib63","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1038\/s41598-020-61027-w","article-title":"Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide","volume":"10","author":"Tateno","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.hoc.2024.01.001_bib64","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3324\/haematol.2020.265611","article-title":"Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma","volume":"106","author":"Costacurta","year":"2021","journal-title":"Haematologica"},{"issue":"7596","key":"10.1016\/j.hoc.2024.01.001_bib65","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature17416","article-title":"Cullin\u2013RING ubiquitin E3 ligase regulation by the COP9 signalosome","volume":"531","author":"Cavadini","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2024.01.001_bib66","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40958","article-title":"UBE2G1 governs the destruction of cereblon neomorphic substrates","volume":"7","author":"Lu","year":"2018","journal-title":"Elife"},{"issue":"16","key":"10.1016\/j.hoc.2024.01.001_bib67","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.2022015909","article-title":"Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma","volume":"140","author":"Gooding","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2024.01.001_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg2697","article-title":"ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.hoc.2024.01.001_bib69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2014.238","article-title":"In\u00a0vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone","volume":"29","author":"Ocio","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2024.01.001_bib70","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12157","article-title":"Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner","volume":"12","author":"Dimopoulos","year":"2018","journal-title":"Mol Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:17:42Z","timestamp":1760591862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858824000017"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.01.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cereblon-Targeting Ligase Degraders in Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}